| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2009PNAS..10617158L |
| P356 | DOI | 10.1073/PNAS.0909520106 |
| P932 | PMC publication ID | 2761323 |
| P698 | PubMed publication ID | 19805176 |
| P5875 | ResearchGate publication ID | 26871354 |
| P2093 | author name string | Sihong Song | |
| Yuanqing Lu | |||
| P2860 | cites work | Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis | Q28213353 |
| Adeno-associated virus serotypes: vector toolkit for human gene therapy | Q33249130 | ||
| Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers | Q33782809 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A. | Q34595095 | ||
| Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer | Q34985105 | ||
| Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6 | Q35024289 | ||
| Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells | Q35186003 | ||
| Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. | Q36438711 | ||
| AAV as an immunogen | Q36990100 | ||
| Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. | Q40168483 | ||
| Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer | Q41920883 | ||
| Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy | Q41999615 | ||
| Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy | Q43801966 | ||
| Ex vivo transduced liver progenitor cells as a platform for gene therapy in mice | Q44147819 | ||
| Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice | Q44719693 | ||
| Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins | Q45384856 | ||
| Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid | Q45414481 | ||
| Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector | Q45419136 | ||
| Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene. | Q45421368 | ||
| Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart | Q45507049 | ||
| Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity | Q45698037 | ||
| Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors | Q45735547 | ||
| Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs | Q45856596 | ||
| AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease. | Q45856667 | ||
| Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice | Q45859046 | ||
| Immune responses to AAV capsid: are mice not humans after all? | Q45866729 | ||
| Erythropoietin gene therapy leads to autoimmune anemia in macaques | Q45871284 | ||
| Surface alpha 2-3- and alpha 2-6-sialylation of human monocytes and derived dendritic cells and its influence on endocytosis | Q46850314 | ||
| Non-obese diabetic (NOD) mice display enhanced immune responses and prolonged survival of lymphoid cells | Q72357662 | ||
| Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells | Q72698982 | ||
| AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease | Q81058015 | ||
| P433 | issue | 40 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 17158-17162 | |
| P577 | publication date | 2009-09-22 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors | |
| P478 | volume | 106 |
| Q36757066 | ACE2 Therapy Using Adeno-associated Viral Vector Inhibits Liver Fibrosis in Mice |
| Q34810340 | Adipose tissue-derived mesenchymal stem cell-based liver gene delivery |
| Q90468943 | Alpha 1 Antitrypsin Gene Therapy Extends the Lifespan of Lupus-Prone Mice |
| Q33671373 | Alpha 1-antitrypsin therapy mitigated ischemic stroke damage in rats |
| Q39587262 | Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model |
| Q93016705 | Alpha-1-Antitrypsin Ameliorates Pristane Induced Diffuse Alveolar Hemorrhage in Mice |
| Q91296268 | Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies |
| Q39394803 | Complexity of immune responses to AAV transgene products - Example of factor IX. |
| Q38959186 | Continuous CD8⁺ T-cell priming by dendritic cell cross-presentation of persistent antigen following adeno-associated virus-mediated gene delivery |
| Q90434853 | Cross-Presentation of Skin-Targeted Recombinant Adeno-associated Virus 2/1 Transgene Induces Potent Resident Memory CD8+ T Cell Responses |
| Q38003108 | Detection of EPO gene doping in blood |
| Q36945745 | Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles |
| Q42175045 | Duchenne muscular dystrophy gene therapy in the canine model |
| Q35641673 | Duchenne muscular dystrophy gene therapy in the canine model. |
| Q37342834 | Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies |
| Q30490945 | Engineering antibody-like inhibitors to prevent and treat HIV-1 infection |
| Q27307010 | Impact of age at administration, lysosomal storage, and transgene regulatory elements on AAV2/8-mediated rat liver transduction |
| Q35451204 | Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer. |
| Q90275153 | In Situ Modification of Tissue Stem and Progenitor Cell Genomes |
| Q92301725 | Innate Immune Response Following AAV Administration |
| Q37939843 | Innate Immune Responses to AAV Vectors |
| Q40117829 | Intradermal Immunization with rAAV1 Vector Induces Robust Memory CD8(+) T Cell Responses Independently of Transgene Expression in DCs. |
| Q42996820 | Intradermal alpha1-antitrypsin therapy avoids fatal anaphylaxis, prevents type 1 diabetes and reverses hyperglycaemia in the NOD mouse model of the disease |
| Q92345037 | Liver-Directed but Not Muscle-Directed AAV-Antibody Gene Transfer Limits Humoral Immune Responses in Rhesus Monkeys |
| Q36940126 | Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver |
| Q45868167 | Longevity of rAAV vector and plasmid DNA in blood after intramuscular injection in nonhuman primates: implications for gene doping |
| Q26745822 | MicroRNA-regulated viral vectors for gene therapy |
| Q44861538 | Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery |
| Q35086714 | Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates |
| Q94547060 | Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics |
| Q37621530 | Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies |
| Q92987777 | Regulated hAAT Expression from a Novel rAAV Vector and Its Application in the Prevention of Type 1 Diabetes |
| Q40084021 | Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler-Najjar Syndrome Type I. |
| Q36756695 | Serotype-specific Binding Properties and Nanoparticle Characteristics Contribute to the Immunogenicity of rAAV1 Vectors |
| Q98945200 | Synthetic immunomodulation with a CRISPR super-repressor in vivo |
| Q38908933 | Systemic delivery of adeno-associated viral vectors |
| Q35067592 | The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver |
| Q37393827 | The role of apoptosis in immune hyporesponsiveness following AAV8 liver gene transfer |
Search more.